190 related articles for article (PubMed ID: 30532240)
1. PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development.
Wilson JL; Racz R; Liu T; Adeniyi O; Sun J; Ramamoorthy A; Pacanowski M; Altman R
PLoS Comput Biol; 2018 Dec; 14(12):e1006614. PubMed ID: 30532240
[TBL] [Abstract][Full Text] [Related]
2. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs.
Hosomi K; Fujimoto M; Ushio K; Mao L; Kato J; Takada M
PLoS One; 2018; 13(10):e0204648. PubMed ID: 30300381
[TBL] [Abstract][Full Text] [Related]
3. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
Xu R; Wang Q
J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
[TBL] [Abstract][Full Text] [Related]
4. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
5. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
6. PathFXweb: a web application for identifying drug safety and efficacy phenotypes.
Wilson JL; Wong M; Chalke A; Stepanov N; Petkovic D; Altman RB
Bioinformatics; 2019 Nov; 35(21):4504-4506. PubMed ID: 31114840
[TBL] [Abstract][Full Text] [Related]
7. Data Integrity: History, Issues, and Remediation of Issues.
Rattan AK
PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
[TBL] [Abstract][Full Text] [Related]
8. Drug voyager: a computational platform for exploring unintended drug action.
Oh M; Ahn J; Lee T; Jang G; Park C; Yoon Y
BMC Bioinformatics; 2017 Feb; 18(1):131. PubMed ID: 28241745
[TBL] [Abstract][Full Text] [Related]
9. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
10. Investigating drug repositioning opportunities in FDA drug labels through topic modeling.
Bisgin H; Liu Z; Kelly R; Fang H; Xu X; Tong W
BMC Bioinformatics; 2012; 13 Suppl 15(Suppl 15):S6. PubMed ID: 23046522
[TBL] [Abstract][Full Text] [Related]
11. Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy Analysis.
Liu L; Tsompana M; Wang Y; Wu D; Zhu L; Zhu R
J Chem Inf Model; 2016 Sep; 56(9):1615-21. PubMed ID: 27508329
[TBL] [Abstract][Full Text] [Related]
12. 'RE:fine drugs': an interactive dashboard to access drug repurposing opportunities.
Moosavinasab S; Patterson J; Strouse R; Rastegar-Mojarad M; Regan K; Payne PR; Huang Y; Lin SM
Database (Oxford); 2016; 2016():. PubMed ID: 27189611
[TBL] [Abstract][Full Text] [Related]
13. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
Beninger P; Murray M
Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
[TBL] [Abstract][Full Text] [Related]
14. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
15. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
16. Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events.
Wang K; Wan M; Wang RS; Weng Z
J Med Internet Res; 2016 Apr; 18(4):e76. PubMed ID: 27036325
[TBL] [Abstract][Full Text] [Related]
17. Drug Repositioning and Target Finding Based on Clinical Evidence.
Kaneko S; Nagashima T
Biol Pharm Bull; 2020; 43(3):362-365. PubMed ID: 32115497
[TBL] [Abstract][Full Text] [Related]
18. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.
Dhodapkar MM; Shi X; Ramachandran R; Chen EM; Wallach JD; Ross JS
BMJ; 2022 Oct; 379():e071752. PubMed ID: 36198428
[TBL] [Abstract][Full Text] [Related]
19. Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives.
Marshall S; Madabushi R; Manolis E; Krudys K; Staab A; Dykstra K; Visser SAG
CPT Pharmacometrics Syst Pharmacol; 2019 Feb; 8(2):87-96. PubMed ID: 30411538
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
